双靶向药物联合TCb方案对HER2阳性乳腺癌新辅助化疗的效果及肿瘤标志物的影响  

Effect of double targeted drugs combined with TCb regimen on neoadjuvant chemotherapy for HER2-positive breast cancer and its influence on tumor markers

作　　者：梁晓丹 张强[1] 柴丽君[1] LIANG Xiao-dan;ZHANG Qiang;CHAI Li-jun(Department of Breast Surgery,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450003,Henan,CHINA)

机构地区：[1]郑州大学第二附属医院乳腺外科,河南郑州450003

出　　处：《海南医学》2024年第20期2921-2925,共5页Hainan Medical Journal

基　　金：河南省科技厅科技攻关项目(编号:182102310140)。

摘　　要：目的探讨双靶向药物联合紫杉醇和铂类(TCb)方案对人表皮生长因子受体2(HER2)阳性乳腺癌新辅助化疗的效果及肿瘤标志物的影响。方法选取2019年6月至2023年6月郑州大学第二附属医院乳腺外科收治的120例HER2阳性乳腺癌患者作为研究对象,按随机数表法将患者分为观察组和对照组各60例。对照组患者采用常规TCb方案治疗,观察组患者则在对照组基础上予以曲妥珠单抗+帕妥珠单抗方案治疗,两组化疗6个周期后均接受手术治疗。比较两组患者手术治疗4周后的临床疗效,以及手术前和手术治疗后4周后的肿瘤生长因子[血管内皮生长因子A(VEGFA)、血管内皮生长因子B(VEGFB)]、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)]水平,同时比较两组患者治疗期间的不良反应发生情况。结果治疗后,观察组患者的疾病控制率为93.33%,客观缓解率为83.33%,明显高于对照组的55.00%和75.00%,差异均有统计学意义(P<0.05);治疗后,观察组患者的VEGFA、VEGFB、CEA、CA125、CA153水平分别为(76.01±6.76)ng/mL、(64.62±6.24)ng/mL、(2.01±0.76)pg/m L、(14.62±5.21)U/m L、(22.16±8.36)U/m L,明显低于对照组的(92.53±8.23)ng/m L、(78.35±7.52)ng/m L、(2.89±1.12)pg/mL、(18.37±5.56)U/mL、(28.55±9.03)U/mL,差异均有统计学意义(P<0.05);治疗期间两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论双靶向药物联合TCb方案可显著提高HER2阳性乳腺癌患者的新辅助化疗的治疗效果,并降低肿瘤生长因子及标志物水平,具有较好的临床应用价值。Objective To explore the effect of double targeted drugs combined with taxol and carboplatin(TCb)regimen on neoadjuvant chemotherapy for human epidermal growth factor receptor 2(HER2)-positive breast cancerand its influence on tumor markers.Methods A total of 120 patients with HER2-positive breast cancer in Departmentof Breast Surgery,the Second Affiliated Hospital of Zhengzhou University from June 2019 to June 2023 were selectedand divided into an observation group and a control group by random number table method,with 60 patients ineach group.The patients in the control group received conventional TCb regimen,whereas those in the observationgroup received trastuzumab+pertuzumab regimen on the basis of the treatment in the control group.Both groups of patientsreceived surgical treatment after 6 cycles of chemotherapy.The clinical efficacy after 4 weeks of surgical treatment,levels of tumor growth factors(vascular endothelial growth factor A,VEGFA;vascular endothelial growth factorB,VEGFB)and tumor markers(carcinoembryonic antigen,CEA;carbohydrate antigen 125,CA125;carbohydrate antigen153,CA153)before surgery and at 4 weeks after surgical treatment and occurrence of adverse reactions during treatmentwere compared between the two groups.Results After treatment,the disease control rate and objective remissionrate were 93.33%and 83.33%in the observation group,which were significantly higher than 55.00%and 75.00%in thecontrol group(P<0.05).After treatment,the levels of VEGFA,VEGFB,CEA,CA125,and CA153 in the observationgroup were(76.01±6.76)ng/mL,(64.62±6.24)ng/mL,(2.01±0.76)pg/mL,(14.62±5.21)U/mL,and(22.16±8.36)U/mL,which were significantly lower than(92.53±8.23)ng/mL,(78.35±7.52)ng/mL,(2.89±1.12)pg/mL,(18.37±5.56)U/mL,and(28.55±9.03)U/mL in the control group(P<0.05).There were no statistically significant differences in the incidenceof adverse reactions between the two groups(P>0.05).Conclusion Double targeted drugs combined with TCb regimencan significantly enhance the therapeutic effect of neoadjuvant ch

关 键 词：HER2阳性乳腺癌 双靶向药物 紫杉醇和铂类 化疗效果 肿瘤标志物 

分 类 号：R737.9[医药卫生—肿瘤]